RxDoctor Payments Data

Jeffrey Konstanz, PA

Physician Assistant · Platte, SDNPI 1699728733

Payments from drug & device makers

$258in general payments, 2019–2025

Across 15 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$43
  • Viatris Specialty LLC$40
  • Amgen$40
  • Novartis$38
  • Boehringer Ingelheim$28
  • Astellas Pharma US Inc$28
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$258100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mylan Specialty L.p.2$43
Viatris Specialty LLC1$40
Amgen3$40
Novartis2$38
Boehringer Ingelheim2$28
Astellas Pharma US Inc2$28
Pelvital USA, Inc.1$20
Pfizer1$14
RARE Disease Therapeutics, Inc.1$5

How this compares

$258 in reported general payments places this provider in the 60th percentile of 548 physician assistant providers in South Dakota.

See all physician assistant providers in South Dakota

Medicare billing

Part B allowed, 2024
$3,321
Medicare patients
44
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$46,678
EliquisApixaban51$42,238
OzempicSemaglutide33$37,305
FarxigaDapagliflozin Propanediol35$28,068
XareltoRivaroxaban36$20,939
Fiasp FlextouchInsulin Aspart (Niacinamide)26$19,935
EntrestoSacubitril/Valsartan40$18,366
JanumetSitagliptin Phos/Metformin Hcl27$17,494
Praluent PenAlirocumab28$16,204
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog43$13,909
MounjaroTirzepatide11$12,008
Breo ElliptaFluticasone/Vilanterol16$6,649
Spiriva HandihalerTiotropium Bromide11$5,947
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,826
Losartan Potassium396$3,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$28$46,67871 claims
PfizerEliquis$14$42,23851 claims
NovartisEntresto$38$18,36640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 548 physician assistant providers in South Dakota.

Other physician assistant in Platte

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →